CCL5

Across TCGA pan-cancer cohorts, CCL5 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CCL5 data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CCL5 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CCL5 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, CCRCC, and PDAC are the cancer types where CCL5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	III,IV	1.000	0.177	.024	25	view →
CCRCC	OS	Quartile	II,III,IV	1.000	0.630	.003	19	view →
PDAC	DFS	Tertile	III,IV	0.557	0.181	.022	13	view →
LUAD	DFS	Tertile	All	0.837	0.439	.022	8	view →
LSCC	OS	Quartile	II,III,IV	0.473	0.929	.004	8	view →
GBM	OS	Median	All	0.581	0.234	.004	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CCL5–HNSC (DFS)

Open the HNSC breakdown →